Government Medical Store Depot Hyderabad
Medical Stores Organization
Directorate General of Health Services
Ministry of Health and Family welfare
Behind ESI Hospital, S.R Nagar, Hyderabad-500038.

Minutes of the Pre-Bid Meeting

Tender No.: GMSDHYD/PS/GROUP-B/99 DRUGS/2026-2027/02
Tender ID: 2026_DGHS_908298_1

Subject: Procurement of 99 Group-B Generic Drugs.

The Pre-Bid Meeting in respect of the above-mentioned tender was held on 15.05.2026 at 11:00 AM in the Hall.No.01 GMSD Hyderabad under the Chairpersonship of Dr. Anju Nanda, DDG (Stores), MSO.

The meeting was attended by officers/officials of GMSD and representatives of prospective bidders. The following departmental officers were present during the meeting:

1. Shri. Dr. Srinivas.S, Senior Medical Officer, Incharge - GMSD Hyderabad
2. Shri. N.V.Janardhana Rao, Senior Accounts Officer, GMSD Hyderabad
3. Shri. Dr. Ch Pradeep, Chief Medical Officer, C.G.H.S Hyderabad (Outside)
4. Smt. T. Rama Chandra Waker, Assistant Depot Manager, GMSD Hyderabad
5. Shri. Pritam Singh, Depot Superintendent
6. Smt. H.Sai Srilatha, Depot Superintendent
7. Shri. G.Vinay Kumar, Depot Superintendent
8. Shri. R.Shailender Singh, Pharmacist cum Clerk

At the outset, the Chairperson welcomed all participants and explained about the procurement policy of MSO and discussed about the procurement of medicines and supply. It is informed that all queries those received by the prospective bidders, mail if any raised during the meeting, shall be addressed. It was further informed that the clarifications issued during the pre-bid meeting shall form an integral part of the tender document.

All queries received were examined and consolidated under thematic areas. The decisions taken are in accordance with tender conditions, GFR 2017, and principles of transparency, fairness, and competition.

Clarifications & Decisions

No modification in eligibility criteria, delivery period, regulatory compliance, and technical specifications was considered necessary unless explicitly clarified. Certain operational clarifications and documentation clarifications have been allowed as detailed in the MOM.

A summary of bidder-wise queries and their disposition is placed at Annexure–I. Detailed clarifications have been issued in thematic form to ensure uniformity and transparency.

With regard to eligibility criteria, including turnover requirements and requests for supply through distributors or C&F agents, it was decided that no modification is warranted. The existing provisions have been framed to ensure reliable supply across all GMSDs, compliance with prescribed storage and distribution norms and timely execution of supply orders.

On the issue of delivery period, several bidders requested extension from 45 days to 60 days citing API shortages and logistical challenges. After due consideration, the request was not accepted. The delivery period as stipulated in the tender, is retained since it is aligned with operational requirements of GMSD/CGHS and is critical to ensuring uninterrupted availability of medicines.

Regarding regulatory compliance, particularly in respect of Fixed Dose Combinations (FDCs), it was clarified that CDSCO/DCGI approval is mandatory wherever applicable. Bidders shall submit valid CDSCO/DCGI approval certificates for FDC drugs (wherever applicable) at the time of bid submission, unless otherwise specified. No relaxation in regulatory requirements is permissible.

With respect to technical specifications, including composition, strength, nomenclature, and pharmacopoeial standards, requests for modifications were examined but not accepted. It is reiterated that the specifications provided in the Schedule of Requirement (SOR) are to be strictly adhered to, and no deviation in composition or strength is permitted until specified further.

In relation to dosage forms, it is clarified that capsule and tablet forms, Ampoules and vials shall be treated at par, unless specifically restricted under applicable pharmacopoeial standards or statutory rules. Value-added formulations such as SR/CR/ER/XR/PR/MR etc are acceptable and will be treated at par for evaluation purposes.

On the matter of packing and pack size, it is clarified that larger pack sizes may be accepted subject to rate equivalence with the pack size specified in the SOR. Alternative pack sizes, such as strip of 15 tablets or capsules, may be considered provided all other tender conditions are complied with. Rates shall be normalized appropriately on a per unit basis wherever required.

Requests for relaxation in shelf-life conditions, including acceptance of products with lower shelf life such as 18 months, will be accepted until approved/specified by Drug Controller. The shelf-life criteria prescribed in the tender document shall remain unchanged and must be strictly complied with.

With regard to documentation requirements, it is clarified that Annual Turnover Certificates, Balance Sheets, and Profit & Loss Statements bearing valid UDIN shall be accepted even if the tender ID is not mentioned. Bidders are required to submit samples of primary packing except for injectables, prior to tender opening as per tender conditions. Third-party manufacturing or marketing arrangements shall not be admissible where specifically restricted under the tender provisions.

It is further informed that necessary corrections in item descriptions, including those identified during the pre-bid stage, shall be issued through a corrigendum on the CPP Portal.

Additional clarifications include that larger pack sizes may be accepted subject to rate parity, and unit-based pricing shall be applicable wherever relevant. Existing Rate Contract holders may continue to supply medicines till the validity of their contracts. The roadmap for procurement cycle has already been communicated and is available on the DVDMS portal.

Further, with regard to registration of manufacturing units with MSO, it is clarified that bidders may submit provisional documents such as proof of application, including receipts or acknowledgements, at the time of bid submission. However, The bidders must ensure that the process of submission of duly completed necessary documents as per MSD-1104 & MSD-1105 and the joint inspection of the Manufacturing Unit is completed within 30 days from the date of opening of Price Bids (BoQs) of the tender, failing which action, as deemed fit under the Terms & Conditions of the bid document, shall be taken by the competent authority.

With respect to submission of Non-Conviction Certificate, it is clarified that the certificate should preferably be general in nature and not organization-specific or tender-specific. In case the certificate is organization-specific or tender-specific, it shall be considered valid only if it pertains specifically to this tender. Certificates issued for any other organization or bearing reference to any other tender shall not be considered acceptable. In cases where the validity period of the certificate is not explicitly mentioned, the same shall be treated as valid for a period of six months from the date of issue.

Regarding API traceability and Batch Manufacturing Record (BMR), it is clarified that relaxation in submission of BMR shall be applicable only in respect of imported products and Biological products where items are accepted based on Inhouse Test Report as per the provisions of the tender document.

With reference to the Bill of Quantities (BOQ), it is clarified that the rate unit indicated as "1" shall be construed as the unit rate for the respective item. Accordingly, bidders are required to quote rates on a per unit basis, such as per tablet, capsule, bottle, tube, respule, inhaler, rotacap, respicap, kit, ampoule, vial, sachet, pre-filled syringe (PFS), oral dispersible strip (ODS), flexipen, cartridge, or any other applicable unit as per the item description.

With regard to submission of the tender document, it is clarified that in view of the large file size, bidders may submit the complete tender document, duly signed and stamped, along with the Integrity Pact as per the prescribed requirements. However, at the time of submission of bids, bidders shall mandatorily submit the first two pages and the last two pages of the tender document, duly signed and stamped by authorized signatory, as a token of acceptance and for reference purposes.

It is clarified that provisions regarding Global Tender Enquiry (GTE) exemption shall be governed strictly as per the applicable provisions of GFR 2017 and the Public Procurement (Make in India) policy, as amended from time to time. No separate deviation is envisaged under this tender.

Annexure–I

Summary of Bidder-wise Queries and their Disposition

Name of the Firm	Queries and request for clarification/amendments raised in the Pre-Bid meeting by the prospective Bidder/s to the Committee	Clarification
1. M/s Dr. Reddy's Labs Ltd.	(i) The representative has raised the query regarding the pack size.	It was clarified that:-The bigger pack size than that of the Schedule of requirement will be acceptable. But the rate must be quoted per unit.
	(ii) The representative also raised the query regarding the shelf life of medicines.	It was clarified that:- If the product is available in the market with both shelf life of 18 Months and 24 Months. Then the product with 24 Months only will be accepted. The items with shelf life less than mentioned in Tender document will be accepted only after permission of CDSCO is obtained.
	(iii)The representative raised the query regarding submission of New Tender Documents and Samples.	It was clarified that:- Integrity pact document must be changed and covering letter of Bid Document with new Tender ID number and date must be submitted. No separate submission of samples is required.
2. M/s Quickmed Healthcare Ltd	We respectfully request a relaxation of the condition regarding the Registration of Firms.	It is clarified that:-Emails/ Letter regarding the Confidential reports must be sent on the same day after completion of the Inspection of Manufacturing units.
	1. Delay at GMSD Level for obtaining the confidential reports from Drug Controlled Administration and Bank. The confidential reports may be accepted by mail.	The mails sent must be monitored. The timeline for completion of registration is 07-08 days by GMSD and MSO after submission of all required documents and fee payment.

		The confidential reports cannot be accepted through mails only physical and hard copies are accepted. The firms are directed not to postpone the inspection dates given by Pharmacologist and Drug Inspector.
	2. Non conviction for continuous period of 02 years.	Non conviction certificate must be for continuous period of last 02 years issued by State DCA within last months from the date of publishing of tender. It was clarified that, If the time line is not mentioned on Non conviction certificate it may be considered for only 06 months as per CDSCO guidelines. Further more if State DCA mentions " so far the firm is not convicted" then the certificate may be considered. Non conviction issued with a particular Tender ID/ Organisation name, then the same will not be considered.
	3. If the GLP certificate is under revalidation, will it be accepted?	As the GLP Certificate / Drug License as part of the GFR, if the certificate is applied for / under process for renewal then it is considered. The certificate renewal must be applied timely before expiry. The firms are directed that Primary, Secondary and Tertiary Labelling must be ISO Certified.

	4. The representative raised the query regarding the Data Logger for the cold chain items which are delivered on the same day of packing and in the Thermacol Boxes.	It was clarified that: DATA Logger is mandatory for Cold Chain Items form manufacturing to final packing. Medicines received in the Thermacol Boxes will be accepted within 72 hours form packing.
	5.Annexure J & STP	It was clarified that STP is exempted for Imported and Biological Products. They are to be accepted on the basis of In house Test Reports. And all the mandatory documents must submitted along with the stocks.
3.Mankind Pharma Ltd.	(i) The representative has raised the query regarding the pack size.	It was clarified that:-The bigger pack size than that of the Schedule of requirement will be acceptable. But the rate must be quoted per unit.

The packing details must be submitted along with the stocks.

These minutes, including all clarifications issued herein, shall form an integral part of the tender document. No further queries shall be entertained after issuance of these minutes.

The meeting concluded with a vote of thanks to the Chair.

R Shailender Singh,
Pharmacist Cum Clerk,
GMSD Hyderabad.

G Vinay Kumar,
Depot Superintendent,
GMSD Hyderabad.

H Sai SriLatha,
Depot Superintendent,
GMSD Hyderabad.

Pritam Singh,
Depot Superintendent,,
GMSD Hyderabad.

T Rama Chandra Waker,
Assistant Depot Manager,
GMSD Hyderabad.

N.V.Janardhana Rao,
Sr Accounts Officer,
GMSD Hyderabad.

Dr.Srinivas .S,
Senior Medical Officer,
(Incharge) GMSD
Hyderabad.

Dr. Ch Pradeep,
Chief Medical Officer,
C.G.H.S Hyderabad.

Dr. Anju Nanda,
DDG (Stores), MSO.
(Chair Person)